Tirzepatide lowered blood sugar and body weight in people with type 2 diabetes while also improving their satisfaction with dietary habits, despite the drug's appetite-suppressing effects.
HbA1c dropped from 7.4% to 6.4%Tirzepatide achieved a full percentage point reduction in HbA1c alongside 6.6 kg of weight loss, while patients also reported feeling better about their dietary habits.
What the researchers found
Tirzepatide treatment in 95 people with type 2 diabetes led to significant reductions in HbA1c (from 7.4% to 6.4%) and body weight (from 77.2 kg to 70.6 kg). Notably, despite tirzepatide's appetite-suppressing effects, patients reported significantly improved diet-related quality of life — specifically their perception of dietary therapy's benefits increased from a median score of 58.3 to 67.7 (p<0.01).
Multiple regression analysis showed that both BMI reduction and improved diet-related quality of life were independent predictors of overall treatment satisfaction, with comparable effect sizes.
Why it matters
Weight loss drugs that suppress appetite might be expected to make eating less enjoyable, reducing quality of life around food. This study found the opposite — patients on tirzepatide actually felt better about their dietary habits. This is important because treatment satisfaction drives long-term adherence, and knowing that patients feel positively about diet changes could support better real-world outcomes.
How the study worked
This was a retrospective cross-sectional study of 95 people with type 2 diabetes treated with tirzepatide. Researchers compared clinical measurements (BMI, HbA1c) and validated questionnaire responses (diet-related quality of life via DDRQOL-R-9, treatment satisfaction via DTSQs) before and after treatment. Spearman correlations and multiple regression analyses were used to identify predictors of satisfaction.
Who was studied
People with type 2 diabetes mellitus (middle-aged and older adults)
What this study cannot tell us
As a retrospective, cross-sectional study without a control group, it cannot establish causation. The sample size of 95 is modest. Patient-reported outcomes may be influenced by overall improvement in health metrics. The study does not report treatment duration or tirzepatide dose details in the abstract.
How to read the evidence
This is a retrospective cross-sectional observational study without a control group, which ranks below randomized controlled trials but provides valuable real-world patient-reported outcome data.
When this study was published
Published in 2025, this is a very recent study reflecting current clinical use of tirzepatide for type 2 diabetes.
The bigger picture
GLP-1/GIP receptor agonists like tirzepatide are transforming diabetes and obesity treatment. This study adds an important quality-of-life dimension — showing that these drugs don't just improve clinical numbers but also positively reshape patients' relationship with food, which matters for long-term treatment success.
Questions still open
- Does the improvement in diet-related quality of life persist over longer treatment periods?
- Would these quality-of-life findings hold in a larger, controlled clinical trial?
- How does tirzepatide's impact on diet satisfaction compare to other GLP-1 receptor agonists like semaglutide?
Common questions
Does tirzepatide make people enjoy food less because it suppresses appetite?
How much weight did patients lose on tirzepatide in this study?
Read the original research
Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.
Diabetes research and clinical practice, 229, 112913
Citation
Kato, Shunsuke; Kokita, Ayaka; Akanuma, Hana; Iwamura, Shogo; Takahashi, Yuya; Kusumi, Ryota; Abe, Sakiko; Sasaki, Kana; Otomo, Hitomi; Ando, Sayaka; Nara, Mitsuhiko; Nara, Aiko; Tadika, Takenobu; Shimizu, Tatsunori; Sato, Takehiro; Morii, Tsukasa; Fujita, Hiroki; Matsuda, Daisuke; Waki, Hironori. (2025). Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.. Diabetes research and clinical practice, 229, 112913. https://doi.org/10.1016/j.diabres.2025.112913